Avanos boosts CEO long-term incentive target
Avanos Medical, Inc. reported a change to its executive compensation program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Avanos Medical, Inc. reported a change to its executive compensation program. Effective beginning in 2026, the Board of Directors increased the target value of the annual long-term incentive grant for Chief Executive Officer David C. Pacitti under the 2021 Long Term Incentive Plan from $5,000,000 to $5,500,000. This adjustment affects the equity-based incentive opportunity for the CEO and does not change reported financial results.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive compensation change did Avanos Medical (AVNS) disclose in this 8-K?
Avanos Medical increased CEO David C. Pacitti’s target annual long-term incentive grant from $5,000,000 to $5,500,000. This change applies under the company’s 2021 Long Term Incentive Plan and adjusts his equity-based incentive opportunity starting with grants effective in 2026.
When does the new long-term incentive target for the Avanos (AVNS) CEO take effect?
The higher long-term incentive target for the Avanos CEO becomes effective beginning in 2026. Grants made for 2026 and later years will reflect the updated $5,500,000 target value under the company’s 2021 Long Term Incentive Plan, as amended.
How much did Avanos (AVNS) increase the CEO’s annual long-term incentive target?
Avanos raised CEO David C. Pacitti’s target annual long-term incentive grant by $500,000, from $5,000,000 to $5,500,000. This adjustment affects the equity-based component of his pay rather than base salary or cash bonuses.
Which compensation plan governs the updated CEO incentive grant at Avanos (AVNS)?
The updated CEO incentive grant is governed by Avanos Medical’s 2021 Long Term Incentive Plan, as amended. The Board approved a higher target value under this plan, setting David C. Pacitti’s annual long-term incentive opportunity at $5,500,000 starting with 2026 awards.
Does this Avanos (AVNS) 8-K include any changes to company financial results?
The 8-K focuses on an executive compensation change and does not report new financial results. It specifically addresses the Board’s decision to increase the CEO’s target annual long-term incentive award value effective beginning in 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: March 06, 2026
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission file number) | (I.R.S. Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices) | (Zip code) | |||||||||||||||||||
Registrant’s telephone number, including area code: (844 ) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 6, 2026, the Board of Directors of Avanos Medical, Inc. (the “Company”) increased the target value of the annual long-term incentive grant to which David C. Pacitti, the Company’s Chief Executive Officer, is eligible under the Company’s 2021 Long Term Incentive Plan, as amended, from $5,000,000 to $5,500,000, effective beginning in 2026.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
| Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | ||||||||||||||
| Date: | March 12, 2026 | By: | /s/ John S. Fischer | |||||||||||
| John S. Fischer Vice President, Head of Legal and Secretary | ||||||||||||||